Skip to main content
SpringerLink
Log in

Maligne epitheliale Tumoren des Corpus uteri (ausschließlich des Karzinosarkoms)

  • Chapter
Praxisbuch Gynäkologische Onkologie

  • 865 Accesses

Auszug

Das Korpusmalignom ist in Mitteleuropa nach den Malignomen von Brust und Kolorektum der dritthäufigste Krebs der Frau. Mit ca. 41% der weiblichen Genitalmalignome ist es das häufigste gynäkologische Malignom im engeren Sinn. Die Inzidenz des Endometriumkarzinoms ist in der Schweiz und in Deutschland hoch und beträgt ca. 24–25 pro 100.000 Frauen/Jahr. Seine altersstandardisierte Mortalität ist mit 3,4 pro 100.000 Frauen/Jahr jedoch relativ gering, da 75% der Endometriumkarzinome im Stadium I diagnostiziert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56: 419–427

    PubMed  CAS  Google Scholar 

  • Aapro MS, Wijk FH van, Bolis G et al. (2003) European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14: 441–448

    Article  PubMed  CAS  Google Scholar 

  • Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ (2000) Stage IVB endometrial carcinoma. The role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78: 85–91

    Article  PubMed  CAS  Google Scholar 

  • Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ (2003) FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 13: 664–672

    Article  PubMed  CAS  Google Scholar 

  • Chan JK, Urban R, Cheung MK, Shin JY et al. (2007) Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer 109: 2454–2460

    Article  PubMed  Google Scholar 

  • Chi DS, Welshinger M, Venkatraman ES, Barakat RR (1997) The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 67: 56–60

    Article  PubMed  CAS  Google Scholar 

  • Creasman W, Odicino F, Maisonneuve P et al. (1998) Carcinoma of the corpus uteri. FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. J Epidemiol Biostatics 1: 35–61

    Google Scholar 

  • Creasman W, Odicino F, Maisonneuve P et al. (2001) Carcinoma of the corpus uteri. FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. J Epidemiol Biostatics 6: 45–86

    Google Scholar 

  • Creutzberg CL, Putten WL van, Koper PC et al. (2000) Surgery and post-operative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355: 1404–11

    Article  PubMed  CAS  Google Scholar 

  • Creutzberg CL, Putten WL van, Koper PC et al. (2003) PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 89: 201–209

    Article  PubMed  Google Scholar 

  • Creutzberg CL, Putten WL van, Warlam-Rodenhuis CC et al. (2004) Post-operative Radiation Therapy in Endometrial Carcinoma Trial. Out-come of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22: 1234–1241

    Article  PubMed  Google Scholar 

  • Dreher E, Bronz L, Eggimann T, Maurer F, Munz E, Haller U (2004) Guide-line: Abklärung von perimenopausalen Blutungsstörungen. Schweiz Ärztez 85: 169–181

    Google Scholar 

  • Fehr MK, Wight E, Haller U (1999) Stellenwert der Chemotherapie in der Behandlung des Endometriumkarzinoms. Gynakol Geburtshilfe Rundsch 39: 110–120

    Article  CAS  Google Scholar 

  • Fleming GF, Filiaci VL, Bentley RC et al. (2004a) Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group Study. Ann Oncol 15: 1173–1178

    Article  PubMed  CAS  Google Scholar 

  • Fleming GF, Brunetto VL, Cella D et al. (2004b) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22: 2159–2166

    Article  PubMed  CAS  Google Scholar 

  • Fujiwara H, Saga Y, Takahashi K, Ohwada M (2008) Omental metastases in clinical stage I endometrioid adenocarcinoma. Int J Gynecol Cancer 18: 165–167

    Article  PubMed  CAS  Google Scholar 

  • Goff BA, Kato D, Schmidt RA et al. (1994) Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54: 264–268

    Article  PubMed  CAS  Google Scholar 

  • Hamilton CA, Cheung MK, Osann K, Chen L (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94: 642–646

    PubMed  CAS  Google Scholar 

  • Hogberg T, Rosenberg P, Kristensen G (2007) A randomized phase-III study on adjuvant treatment with radiation chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol 25: 274s

    Google Scholar 

  • Karlsson B, Granberg S, Wikland M et al. (1995) Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding — a Nordic multicenter study. Am J Obstet Gynecol 172: 1488–1494

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann M, Costa SD, Scharl A (Hrsg) (2003) Die Gynäkologie. Springer, Berlin Heidelbeg New York

    Google Scholar 

  • Kilgore L C, Partridge E E, Alvarez R D, Austin J M, Shingleton H M, Noojin F 3rd, Conner W (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56: 29–33

    Article  PubMed  CAS  Google Scholar 

  • Kitchener H, Redman C, Swart A, Amos C (2006) ASTEC — A study in the treatment of endometrial cancer: A randomised trial of lymph-adenectomy in the treatment of endometrial cancer. Gynecol Oncol 101: S21

    Google Scholar 

  • Maggi R, Lissoni A, Spina F (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95: 266–271

    Article  PubMed  CAS  Google Scholar 

  • Mariani A, Webb M J, Keeney G L, Aletti G, Podratz K C (2002) Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol 86: 38–44

    Article  PubMed  Google Scholar 

  • Mariani A, Dowdy S, Cliby W et al. (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging. Gynecol Oncol 109 (2008) 11–18

    Article  PubMed  Google Scholar 

  • Martin-Hirsch P L, Jarvis G, Kitchener H, Lilford R (1999) Progestagens for endometrial cancer. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD001040. DOI: 10.1002/14651858. CD001040

    Google Scholar 

  • Minckwitz von G, Loibl S, Brunnert K (2002) Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer — a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer 38: 2265–2271

    Article  Google Scholar 

  • Morrow CP, Bundy BN, Homesley HD et al. (1990) Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 36: 166–171

    Article  PubMed  CAS  Google Scholar 

  • Morrow CP, Bundy BN, Kurman RJ et al. (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group Study. Gynecol Oncol 40: 55–65

    Article  PubMed  CAS  Google Scholar 

  • Pothuri B, Ramondetta L, Deavers M et al. (2005) Prognosis of radiation-associated endometrial cancers compared to sporadic endometrial cancers. Gynecol Oncol 96: 1004

    Article  Google Scholar 

  • Randall ME, Brunetto G, Muss H et al. (2003) Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 22: 2

    Google Scholar 

  • Randall M E, Filiaci V L, Muss H, Spirtos N M, Mannel R S, Fowler J, Thigpen J T, Benda J A; Gynecologic Oncology Group Study (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24: 36–44

    Article  PubMed  CAS  Google Scholar 

  • Schuenemann H, Jourdain M (1994) Double and triple neoplasms in endometrial carcinoma. Zentralbl Gynäkol 116: 522–526

    Google Scholar 

  • Senkus-Konfeka E, Konfeka T, Jassem J (2004) The effects of tamoxifen on the female genital tract. Cancer Treat Rev 30: 291–301

    Article  Google Scholar 

  • Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA (2003) Tumours of the uterine corpus. In: Tavassoli FA, Devilee P (eds) Tumours of the breast and female genital organs. IARC Press, Lyon, pp 221–232

    Google Scholar 

  • Slomovitz B M, Burke T W, Eifel P J (2003) Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91: 463–469

    Article  PubMed  Google Scholar 

  • Susumu N, Sagae S, Udagawa Y (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108: 226–233

    Article  PubMed  CAS  Google Scholar 

  • Tebeu P M, Popowski Y, Verkooijen H M, Bouchardy C, Ludicke F, Usel M, Major A L (2004) Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis. Br J Cancer 91: 720–724

    PubMed  Google Scholar 

  • Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 12: 1408–1414

    PubMed  CAS  Google Scholar 

  • Thigpen JT, Brady MF, Alvarez RD et al. (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17: 1736–1744

    PubMed  CAS  Google Scholar 

  • Thigpen JT, Brady MF, Homesley HD et al. (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22: 3902–3908

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Frauenklinik Kantonsspital Frauenfeld, Postfach, 8501, Frauenfeld, Schweiz

    Priv.-Doz. Dr. med. Mathias K. Fehr

  2. Klinik für Gynäkologie, Universitätsspital Zürich, Frauenklinikstrasse 10, 8091, Zürich, Schweiz

    Prof. Dr. med. Daniel Fink

Authors
  1. Priv.-Doz. Dr. med. Mathias K. Fehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Daniel Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Geburtshilflich-gynäkologische Universitätsklinik für Frauenheilkunde und Geburtshilfe der Medizinischen Universität Graz, Auenbruggerplatz 14, 8036, Graz, Österreich

    Edgar Petru

  2. Universitätsfrauenklinik Schleswig-Holstein, Campus Kiel Michaelisstraße 16, 24105, Kiel

    Walter Jonat

  3. Klinik für Gynäkologie, Universitätsspital Zürich, Frauenklinikstrasse 10, 8091, Zürich, Schweiz

    Daniel Fink

  4. Privatklinik Zürich-Bethanien Gynäkologisch-onkologisches Ambulatorium, Gynäkologisch-onkologische Praxis und Brustzentrum, Rämistrasse 35, 8001, Zürich, Schweiz

    Ossi Köchli

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Fehr, M.K., Fink, D. (2009). Maligne epitheliale Tumoren des Corpus uteri (ausschließlich des Karzinosarkoms). In: Petru, E., Jonat, W., Fink, D., Köchli, O. (eds) Praxisbuch Gynäkologische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78327-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-78327-5_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-78326-8

  • Online ISBN: 978-3-540-78327-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation